astacin like metalloendopeptidaseGenealiases: OOMD11 · OZEMA11 · SAS1B
Q-omics provides the consensus-scored ASTL profile across patient tissues and cancer cell-line models. ASTL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ASTL is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ASTL RNA expression shows 13,990 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, COAD, and THYM as cancer lineages where ASTL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASTL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASTL survival associations across molecular data types. ASTL RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASTL RNA expression–survival associations across cancer types. High ASTL expression shows unfavorable associations in COAD, but favorable associations in UCS, HNSC, BRCA, SKCM and SCLC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ASTL RNA expression.
This table summarizes ASTL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ASTL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASTL shows lower tumor expression in COAD and KIRP and higher tumor expression in LUSC, UCEC, CHOL and STAD. The COAD box plot shows higher ASTL RNA expression in normal versus tumor tissue (log2 FC = −0.250, t-test p = .002).
This table shows molecular features associated with ASTL in patient tissues and cancer cell lines. In patient samples, ASTL shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ASTL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
